Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Jaap J Zwaginga¹, Bronno van der Holt², Peter A Te Boekhorst³, Bart J Biemond⁴, Mark-David Levin⁵, René van der Griend⁶, Anneke Brand⁷, Sonja Zweegman⁸, Hans F M Pruijt⁹, Vera M J Novotny¹⁰, Art Vreugdenhil¹¹, Marco R de Groot¹², Okke de Weerdt¹³, Elisabeth C M van Pampus¹⁴, Tanja M van Maanen-Lamme¹⁵, Shulamiet Wittebol¹⁶, Martin R Schipperus¹⁷, Matthijs H Silbermann¹⁸, Peter C Huijgens⁸, Marleen Luten², Rene Hollestein², Jan A C Brakenhoff¹⁹, Jolanda G Schrama²⁰, Fransje A A Valster²¹, Gerjo A Velders²², Harry R Koene¹³; Dutch HOVON 64 study group

Affiliations

¹ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands j.j.zwaginga@lumc.nl.
² HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
³ Dept. of Hematology, Erasmus MC, Rotterdam.
⁴ Dept. of Hematology, Academic Medical Center Amsterdam, The Netherlands.
⁵ Dept. of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
⁶ Department of Internal Medicine, Diakonessenhuis, Utrecht.
⁷ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands.
⁸ Dept. of Hematology, VU University Medical Center, Amsterdam.
⁹ Dept. of Internal Medicine, Jeroen Bosch Hospital, Den Bosch.
¹⁰ Dept. of Hematology, Radboud University Medical Centre, Nijmegen.
¹¹ Dept of Internal Medicine, Máxima Medical Center, Veldhoven.
¹² Dept. of Internal Medicine, Medisch Spectrum Twente, Enschede.
¹³ Dept. of Internal Medicine, St. Antonius Hospital, Nieuwegein.
¹⁴ Dept. of Laboratory Medicine, Radboud University Medical Center, Nijmegen.
¹⁵ Dept. of Internal Medicine, Westfriesgasthuis, Hoorn.
¹⁶ Dept. of Internal Medicine, Meander Hospital, Amersfoort.
¹⁷ Dept. of Internal Medicine, HagaZiekenhuis, Den Haag.
¹⁸ Dept. of Internal Medicine, Tergooiziekenhuizen, Blaricum.
¹⁹ Waterland hospital, Purmerend.
²⁰ Dept. of Internal Medicine, Spaarne hospital, Hoofddorp.
²¹ Dept. of Internal Medicine, Lievensberg Hospital, Bergen op Zoom, The Netherlands.
²² Dept. of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands.

PMID: 25425692
PMCID: PMC4349285
DOI: 10.3324/haematol.2014.110213

Clinical Trial

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Jaap J Zwaginga et al. Haematologica. 2015 Mar.

. 2015 Mar;100(3):e90-2.

doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25.

Authors

Affiliations

¹ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands j.j.zwaginga@lumc.nl.
² HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
³ Dept. of Hematology, Erasmus MC, Rotterdam.
⁴ Dept. of Hematology, Academic Medical Center Amsterdam, The Netherlands.
⁵ Dept. of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
⁶ Department of Internal Medicine, Diakonessenhuis, Utrecht.
⁷ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands.
⁸ Dept. of Hematology, VU University Medical Center, Amsterdam.
⁹ Dept. of Internal Medicine, Jeroen Bosch Hospital, Den Bosch.
¹⁰ Dept. of Hematology, Radboud University Medical Centre, Nijmegen.
¹¹ Dept of Internal Medicine, Máxima Medical Center, Veldhoven.
¹² Dept. of Internal Medicine, Medisch Spectrum Twente, Enschede.
¹³ Dept. of Internal Medicine, St. Antonius Hospital, Nieuwegein.
¹⁴ Dept. of Laboratory Medicine, Radboud University Medical Center, Nijmegen.
¹⁵ Dept. of Internal Medicine, Westfriesgasthuis, Hoorn.
¹⁶ Dept. of Internal Medicine, Meander Hospital, Amersfoort.
¹⁷ Dept. of Internal Medicine, HagaZiekenhuis, Den Haag.
¹⁸ Dept. of Internal Medicine, Tergooiziekenhuizen, Blaricum.
¹⁹ Waterland hospital, Purmerend.
²⁰ Dept. of Internal Medicine, Spaarne hospital, Hoofddorp.
²¹ Dept. of Internal Medicine, Lievensberg Hospital, Bergen op Zoom, The Netherlands.
²² Dept. of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands.

PMID: 25425692
PMCID: PMC4349285
DOI: 10.3324/haematol.2014.110213

No abstract available

Keywords: early response; immune thrombocytopenia; open label phase II; rituximab; splenectomy delaying.

PubMed Disclaimer

Figures

**Figure 1.**
Relapse Free Survival (additional file).

See this image and copyright information in PMC

References

1. Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–398. - PubMed
1. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995. - PMC - PubMed
1. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long- term follow-up results. Eur J Haematol. 2008;81(3): 165–169. - PubMed
1. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–334. - PubMed
1. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura–results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004. - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Affiliations

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Authors

Affiliations

Figures

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources